Efficacy and safety of photodynamic therapy mediatied by 5-aminolevulinic acid for the treatment of cervical in low-grade squamous intraepithelial lesions combined with high-risk human papillomavirus in patients of childbearing age: A retrospective analysis.

Revolutionizing hepatic fibrosis staging: A machine learning approach combining clinical, biochemical, and microbiome insights.

Characteristics of online medication consultation from home-based patients on a tertiary hospital WeChat platform: a cross-sectional study.

Daily ultrasound can reduce days of fibrinolytic therapy for pediatric parapneumonic effusion: a retrospective analysis

Treatment outcomes and drug-related adverse events across four short-course RR-TB regimens in South Africa: A retrospective analysis.

This study aimed to explore factors associated with the likelihood of surgical resection after triple-combination conversion therapy in patients with initially unresectable hepatocellular carcinoma (uHCC) and to develop an exploratory predictive model. A retrospective analysis was conducted using clinical data from 210 patients with uHCC who underwent triple-combination conversion therapy at Sichuan Cancer Hospital between January 2022 and January 2025. Patients were randomly assigned to a training cohort (n=147) and a validation cohort (n=63) in a 7:3 ratio. Least absolute shrinkage and selection operator (LASSO) regression was applied to screen candidate predictors, followed by multivariate logistic regression to identify factors associated with surgical conversion. A nomogram was constructed based on these variables, and its discriminative ability, calibration, and potential clinical utility were internally assessed using receiver operating characteristic (ROC) analysis, calibration plots, the Hosmer-Lemeshow test, and decision curve analysis (DCA). Among the 210 patients, 47 (22.4%) successfully underwent conversion and radical resection. Multivariate logistic regression analysis suggested that lower tumor burden score (TBS; OR=0.663), lower neutrophil-to-lymphocyte ratio (NLR; OR=0.572), lower C-reactive protein-to-albumin ratio (CAR; OR=0.057), and absence of cirrhosis (OR=0.289) were associated with a higher likelihood of successful surgical conversion (P<0.05). The nomogram showed moderate to good discriminative performance, with areas under the ROC curve (AUCs) of 0.850 (95% CI: 0.784-0.915) in the training cohort and 0.871 (95% CI: 0.783-0.962) in the validation cohort. Calibration plots and decision curve analysis provided descriptive information regarding model performance within the study cohort. The proposed nomogram, incorporating TBS, NLR, CAR, and cirrhosis status, represents an exploratory tool for estimating the probability of surgical conversion following triple-combination therapy in patients with uHCC. While the model may provide supplementary information to support clinical assessment and patient stratification, further multicenter and prospective studies are required to externally validate and refine its performance before broader clinical application.

Rising U.S. mortality associated with coexisting obstructive sleep apnea and obesity, 1999-2019.

Age-related differences in postoperative outcomes following colectomy for diverticular disease: a National Surgical Quality Improvement Program study.

A novel multidimensional classification system for bone graft healing assessment in guided bone regeneration.

The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis and evaluation of TAFRO syndrome: a review of cases and literature.

Trigeminal neuralgia (TN) is a pain condition characterized by paroxysmal, electric shock-like facial pain, affecting one or more areas of the branches. Approximately 33%-50% of patients require invasive treatment. Radiofrequency thermocoagulation (RFTC) is an established method for managing drug-resistant and chronic TN. This study evaluates treatment response quality and complication rates in repeated RFTC procedures for TN patients. In this retrospective analysis, patient records were extracted from the electronic medical records of Kuopio University Hospital, using the trigeminal neuralgia diagnosis code and the procedure code for thermal destruction of a cranial nerve. Data collected included sex, age, treatment outcomes at 3-month follow-up, presence of complications, technical details, and procedural success for each intervention. Data from 140 patients were analyzed. An excellent or good response was observed in 79% of patients after the first procedure, 62.9% after the second, and 42.3% after the third. Complication rates were 15.7%, 19.6%, and 42.9%, respectively. Logistic regression analysis showed that complication risk was significantly associated with tertiary procedure and female sex. Development of painful post-traumatic trigeminal neuropathy (PTTN) was more common after repeated interventions; 1.4% after the first, 3.1% after the second, and 13.8% after the third procedure. RFTC is an effective and safe method for treatment for persistent trigeminal neuralgia when conservative treatment fails. However, its benefits diminish, and risks increase with each additional procedure, particularly the third. Based on these findings, reintervention should generally be limited to a single repeat procedure.

Control of nocturnal hypoglycemia by CGM-based AI-enabled nocturnal hypoglycemia prediction: A retrospective analysis of real-world data.

The modified Baveno classification for obstructive sleep apnoea: design of a pan-European prospective study.

The application value of indocyanine green in assisting vascular identification during microsurgical varicocelectomy in children.

Evaluating SEAS5 ECMWF seasonal forecasts for Sicily Mediterranean Island: Retrospective analysis and bias correction

Additive effect of free-choice olfactory training combined with pharmacotherapy: A retrospective analysis of post-viral olfactory dysfunction.

Mucormycosis is a rapidly progressive and highly lethal fungal infection in liver transplant recipients, with early diagnosis remaining a major challenge. This study aimed to evaluate the clinical utility of metagenomic next-generation sequencing (mNGS) for early detection and management of perioperative mucormycosis in adult liver transplant patients. A retrospective analysis was conducted on 539 adult patients who underwent liver transplantation between June 2022 and August 2025 at a single tertiary center. Nine patients with clinically confirmed perioperative mucormycosis, in whom mNGS was the first positive diagnostic tool, were included. Clinical characteristics, diagnostic modalities, antifungal strategies, and outcomes were systematically reviewed. Mucormycosis was identified in 1.67% (9/539) of liver transplant recipients. All patients were male with a median age of 51 years. Pulmonary mucormycosis was the most common presentation (n = 5), followed by disseminated (n = 3) and cutaneous infection (n = 1). In all cases, mNGS provided the earliest microbiological evidence, preceding culture and histopathology. Species detected included Cunninghamella spp., Rhizopus microsporus, and Rhizomucor pusillus. The mortality rate of disseminated disease was 100%, whereas localized pulmonary and cutaneous infections had a combined cure or improvement rate of 66.7%. Early targeted antifungal therapy guided by mNGS (amphotericin B formulations combined with posaconazole or isavuconazole) was associated with improved outcomes in nondisseminated cases. mNGS enables earlier detection of perioperative mucormycosis compared to conventional diagnostic methods and supports timely initiation of targeted therapy. Rapid mNGS-guided intervention may prevent progression to disseminated disease and improve prognosis in liver transplant recipients. Integration of mNGS into the diagnostic workflow is recommended for high-risk patients with unexplained pulmonary or cutaneous lesions.

Clinical performance and durability of short taper-wedge femoral stems in direct anterior total hip arthroplasty: Insights from a five-year retrospective analysis.

Lightweight interpretable AI model using multiple blood parameters for emergency diagnosis of acute appendicitis.

Long-term survival for high-risk neuroblastoma has increased from 40% to 60% by optimizing chemotherapy, surgery, radiation therapy, and the addition of anti-GD2 antibody therapy. However, the high cost of this antibody presents access issues globally. This study evaluates the availability, financial coverage, and barriers to accessing these therapies across diverse healthcare settings. An online survey collected data on demographics, treatment practices, financial coverage, regulatory status, and barriers to anti-GD2 therapy. Fisher's exact test was used to compare categorical variables between high-income countries (HICs) and low- and middle-income countries (LMICs). A retrospective cost analysis estimated the financial burden of anti-GD2 therapies using standardized dosing for a representative 3-year-old patient. Responses came from 100 facilities in 80 cities and 59 countries. Anti-GD2 therapy for frontline maintenance was available in 93% of HIC centers, but only 21% of LMIC centers; 65% of LMIC centers reported no access, while the remainder had limited or irregular availability (p < 0.0001, Fisher's exact test). When unavailable, isotretinoin was most often used alone. Financial coverage differed significantly: HICs relied on government or insurance funding, while LMICs depended on out-of-pocket or non-profit support. Cost analysis showed a full treatment course would cost approximately $192,750 for dinutuximab, $142,695 for dinutuximab beta, and $610,800 for naxitamab, highlighting the substantial financial burden these therapies impose. Global access to anti-GD2 therapy is highly unequal. Strategic measures, including negotiations for reduced drug costs, research-based access, and WHO Essential Medicines List inclusion, could help address these disparities.